News Releases

Orgenesis Approved for Additional European Grant for Further Development of its Type 1 Diabetes Program
Apr 13, 2016

Orgenesis Among the Top 10 Regenerative Medicine and Stem Cell Companies to Speak at BIT’s 9th World Congress of Regenerative Medicine & Stem Cell-South Korea
Mar 15, 2016

ORGENESIS NOTE HOLDERS ELECT TO CONVERT $950,000 OF OUTSTANDING NOTES
Dec 29, 2015

ORGENESIS SECURES $10 MILLION IN FINANCING AND RETAINS OWNERSHIP OF MASTHERCELL SA
Dec 16, 2015

Lyfebulb Connect Hosts Event in New York City with Orgenesis, With Focus on Working Toward A Practical Cure for Type 1 Diabetes
Dec 07, 2015

Orgenesis CEO to Speak on Innovations in Diabetes Panel at IDEA Summit
Nov 30, 2015

Orgenesis and Biosequel Enter Collaboration Agreement for Conducting Clinical Trials for Type 1 Diabetes Treatment in Russia
Nov 24, 2015

Lyfebulb and Orgenesis Form Strategic Collaboration with Focus on Delivering a Patient-Centered Practical Cure for Type 1 Diabetes
Nov 23, 2015

Orgenesis to Deliver Presentation and Poster Session at World Congress of Regenerative Medicine & Stem Cell in Shanghai, China
Nov 17, 2015

Orgenesis CEO to Participate in Diabetes Panel at BIO-Europe 2015
Oct 30, 2015

12345>>>

 


RSS Feed

icon-rss Preview or subscribe to our news feed here.

 


Historical Press Releases

This website contains historical and archived press releases for Orgenesis Inc. The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Orgenesis Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.


Back to Top